Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL
项目 2:优化氧化还原调节作为 NHL 的治疗策略
基本信息
- 批准号:8321622
- 负责人:
- 金额:$ 20.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:ATP-Dependent ProteasesAftercareAntioxidantsApoptoticBiologicalBiological MarkersCell DeathCellsClinicClinicalClinical DataClinical TrialsClinical Trials DesignDataDefense MechanismsDevelopmentDiffuseDiffuse Large-Cell LymphomaDrug CombinationsDrug Delivery SystemsFamilyGenerationsGoalsHistone Deacetylase InhibitorIn VitroLaboratory StudyLeadLearningLymphomaMantle Cell LymphomaMediatingMitochondriaNon-Hodgkin&aposs LymphomaOxidation-ReductionOxidative StressPatientsPeptide HydrolasesPhaseProteasome InhibitorProteinsPublishingReactive Oxygen SpeciesRefractoryRelapseResearch DesignSamplingScheduleSystemTestingTherapeuticThioredoxinXenograft Modelacivicinbasecytotoxiccytotoxicityendopeptidase Lain vivoinhibitor/antagonistinsightinterestmulticatalytic endopeptidase complexnovelnovel therapeutic interventionnovel therapeuticsoleananepre-clinicalresearch clinical testingtumor
项目摘要
Project 2:
The triterpenoids are novel electrophilic compounds that we have shown induce apoptotic cell death in
mantle cell lymphoma (MCL) and diffuse large cell lymphoma (DLCL). Indeed our published and preliminary
studies suggest that these compounds manifest their cytotoxic effects by both increasing the generation of
reactive oxygen species (ROS), and decreasing the activity of such critical anti-oxidant defense mechanisms
as thioredoxin (Trx) and the mitochondria! proteases, Lon and CIpXP. This suggests a novel therapeutic
strategy for lymphoma based on modulating the lymphoma cell redox state. In addition, our proposed
mechanism suggests that other redox active agents, such as proteosome inhibitors and histone deacetylase
inhibitors, are rationale agents to combine with the triterpenoids. The Specific Aims of this proposal have
been developed to provide the essential pre-clinical data needed to support the clinical evaluation of the
optimal triterpenoid and other redox active agent combinations for patients with DLCL and MCL.
Specifically, in Specific Aim 1, we will validate our proposed mechanism of activity of the triterpenoids so to
optimize triterpenoid drug combinations in vitro. These combinations will be further optimized and the
biological targets of ROS generation, Trx and mitochondrial proteases validated in vivo using DLCL and
MCL/SCID xenograft models in Specific Aim 2. We anticipate that the data derived from these Specific Aims
will suggest an optimal triterpenoid combination, and sequence of drug delivery to be studied in the context
of a phase l/ll trial as proposed in Specific Aim 3. A critical component of this trial will be the correlative
laboratory studies whereby we propose to determine the in vivo effects of this drug combination on ROS, Trx
and mitochondrial protease activity in patients with lymphoma. It is further anticipated that the lessons
learned from these studies will support our long term goals which are to understand the clinical potential of
the family of electrophilic compounds in NHL, which also includes the parthenolides, cucurmin, and the
acivicins, and more importantly how best to exploit the redox state of lymphoma to generate new and
effective approaches for the treatment of patients with NHL.
项目2:
三萜类化合物是一种新的亲电化合物,我们已经证明它能诱导细胞凋亡。
套细胞淋巴瘤(MCL)和弥漫性大细胞淋巴瘤(DLCL)。事实上,我们出版的和初步的
研究表明,这些化合物显示了它们的细胞毒性作用,既增加了
活性氧物种(ROS),并降低这种关键的抗氧化防御机制的活性
硫氧还蛋白(Trx)和线粒体!蛋白水解酶、LON和CIPXP。这表明了一种新的治疗方法
基于调节淋巴瘤细胞氧化还原状态的淋巴瘤治疗策略。此外,我们建议的
机制表明,其他氧化还原活性物质,如蛋白酶体抑制剂和组蛋白脱乙酰酶
抑制剂,是与三萜类化合物结合的基本试剂。这项提案的具体目标有
以提供必要的临床前数据,以支持对
DLCL和MCL患者的最佳三萜类和其他氧化还原活性药物组合。
具体地说,在具体目标1中,我们将验证我们提出的三萜类化合物的活性机理,以便
体外优化三萜类药物组合。这些组合将进一步优化,并将
DLCL和DLCL体内验证ROS生成、TRX和线粒体蛋白酶的生物学靶点
特定靶点的MCL/SCID异种移植模型2.我们预计来自这些特定靶点的数据
将提出一种最佳的三萜类化合物组合,以及将在上下文中研究的给药顺序
具体目标3.本试验的一个关键组成部分将是相关的
我们建议确定该药物组合对ROS、TRX的体内影响的实验室研究
淋巴瘤患者的线粒体蛋白水解酶活性。进一步预计,这些经验教训
从这些研究中学到的知识将支持我们的长期目标,即了解
非霍奇金淋巴瘤中的亲电化合物家族,其中还包括巴特烯内酯、葫芦素和
更重要的是,如何最好地利用淋巴瘤的氧化还原状态来产生新的和
治疗非霍奇金淋巴瘤的有效方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN H BERNSTEIN其他文献
STEVEN H BERNSTEIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN H BERNSTEIN', 18)}}的其他基金
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
利妥昔单抗在淋巴瘤患者中引发肿瘤特异性 T 细胞反应
- 批准号:
8068292 - 财政年份:2008
- 资助金额:
$ 20.87万 - 项目类别:
P- 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL
P- 2:优化氧化还原调节作为 NHL 的治疗策略
- 批准号:
7507431 - 财政年份:2008
- 资助金额:
$ 20.87万 - 项目类别:
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
利妥昔单抗在淋巴瘤患者中引发肿瘤特异性 T 细胞反应
- 批准号:
7373337 - 财政年份:2008
- 资助金额:
$ 20.87万 - 项目类别:
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
利妥昔单抗在淋巴瘤患者中引发肿瘤特异性 T 细胞反应
- 批准号:
8260463 - 财政年份:2008
- 资助金额:
$ 20.87万 - 项目类别:
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
利妥昔单抗在淋巴瘤患者中引发肿瘤特异性 T 细胞反应
- 批准号:
7817051 - 财政年份:2008
- 资助金额:
$ 20.87万 - 项目类别:
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
利妥昔单抗在淋巴瘤患者中引发肿瘤特异性 T 细胞反应
- 批准号:
7628573 - 财政年份:2008
- 资助金额:
$ 20.87万 - 项目类别:
Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL
项目 2:优化氧化还原调节作为 NHL 的治疗策略
- 批准号:
8131040 - 财政年份:
- 资助金额:
$ 20.87万 - 项目类别:
Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL
项目 2:优化氧化还原调节作为 NHL 的治疗策略
- 批准号:
8381186 - 财政年份:
- 资助金额:
$ 20.87万 - 项目类别:
相似海外基金
Life outside institutions: histories of mental health aftercare 1900 - 1960
机构外的生活:1900 - 1960 年心理健康善后护理的历史
- 批准号:
DP240100640 - 财政年份:2024
- 资助金额:
$ 20.87万 - 项目类别:
Discovery Projects
Development of a program to promote psychological independence support in the aftercare of children's homes
制定一项计划,促进儿童之家善后护理中的心理独立支持
- 批准号:
23K01889 - 财政年份:2023
- 资助金额:
$ 20.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
- 批准号:
10452217 - 财政年份:2022
- 资助金额:
$ 20.87万 - 项目类别:
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
- 批准号:
10670838 - 财政年份:2022
- 资助金额:
$ 20.87万 - 项目类别:
Aftercare for young people: A sociological study of resource opportunities
年轻人的善后护理:资源机会的社会学研究
- 批准号:
DP200100492 - 财政年份:2020
- 资助金额:
$ 20.87万 - 项目类别:
Discovery Projects
Creating a National Aftercare Strategy for Survivors of Pediatric Cancer
为小儿癌症幸存者制定国家善后护理策略
- 批准号:
407264 - 财政年份:2019
- 资助金额:
$ 20.87万 - 项目类别:
Operating Grants
Aftercare of green infrastructure: creating algorithm for resolving human-bird conflicts
绿色基础设施的善后工作:创建解决人鸟冲突的算法
- 批准号:
18K18240 - 财政年份:2018
- 资助金额:
$ 20.87万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an aftercare model for children who have experienced invasive procedures
为经历过侵入性手术的儿童开发善后护理模型
- 批准号:
17K12379 - 财政年份:2017
- 资助金额:
$ 20.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a Comprehensive Aftercare Program for children's self-reliance support facility
为儿童自力更生支持设施制定综合善后护理计划
- 批准号:
17K13937 - 财政年份:2017
- 资助金额:
$ 20.87万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Project#2 Extending Treatment Effects Through an Adaptive Aftercare Intervention
项目
- 批准号:
8742767 - 财政年份:2014
- 资助金额:
$ 20.87万 - 项目类别: